Abeona Therapeutics Announces Initial European Regulatory Approvals for Phase 1/2 Gene Therapy Clinical Studies for Sanfilippo Syndromes Type A and B

Abeona Therapeutics, Inabeona-logoc. has announced that the Interministerial Council of Genetically Modified Organisms has approved the Genetically Modified Organism (GMO) Voluntary Release regulatory filings for both Phase 1/2 Gene Therapy Clinical Studies to treat patients with Sanfilippo syndrome type A (MPS IIIA) or type B (MPS IIIB).

Read the full press release here.

This entry was posted in News. Bookmark the permalink.

Comments are closed.